Literature DB >> 31006562

Comorbid hypertension in patients with major depressive disorder - Results from a European multicenter study.

Gernot Fugger1, Markus Dold1, Lucie Bartova1, Alexander Kautzky1, Daniel Souery2, Julien Mendlewicz3, Alessandro Serretti4, Joseph Zohar5, Stuart Montgomery6, Richard Frey1, Siegfried Kasper7.   

Abstract

The objective of the present multicenter study was to elucidate relevant associations between major depressive disorder (MDD) and comorbid hypertension that are known for their frequent co-occurrence and interaction with regard to functional disability. Demographic and clinical information of altogether 1410 patients were retrieved cross-sectionally. Consecutively, a comparison of patient characteristics between MDD subjects with and without comorbid hypertension were conducted by descriptive statistics, analyses of covariance (ANCOVA) and binary logistic regression analyses. The point prevalence rate for comorbid hypertension was 18.9%. Patients with MDD+comorbid hypertension were significantly older, heavier, more likely to be in a relationship, inpatient and diagnosed with further comorbid chronic somatic diseases including heart disease, diabetes and thyroid dysfunction. In addition, individuals with MDD and comorbid hypertension exhibited a higher score at the Montgomery and Åsberg Depression Rating Scale (MADRS) at onset of the current depressive episode. Melancholic features of depression showed a higher probability. The first line antidepressant treatment did not differ significantly between MDD subjects with versus without comorbid hypertension. Augmentation with pregabalin and combination with one additional antidepressant, however, were more common in the MDD+hypertension group. In conclusion, high blood pressure may influence illness severity and is associated with a distinct psychopathology in MDD patients. Patients with MDD and comorbid hypertension, that seems to be underdiagnosed in MDD patients compared to the general population, are subject to additional somatic diseases in almost 100 percent of the cases and hence, need to be screened and treated accordingly.
Copyright © 2019 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Clinical aspects; Comorbidity; Depression; Physical illness

Year:  2019        PMID: 31006562     DOI: 10.1016/j.euroneuro.2019.03.005

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  5 in total

1.  Disease Trajectories for Hidradenitis Suppurativa in the Danish Population.

Authors:  Rune Kjærsgaard Andersen; Isabella Friis Jørgensen; Roc Reguant; Gregor Borut Ernst Jemec; Søren Brunak
Journal:  JAMA Dermatol       Date:  2020-07-01       Impact factor: 10.282

Review 2.  Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness.

Authors:  Victor Mazereel; Johan Detraux; Davy Vancampfort; Ruud van Winkel; Marc De Hert
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-09       Impact factor: 5.555

Review 3.  Is Mindfulness-Based Stress Reduction Effective for People with Hypertension? A Systematic Review and Meta-Analysis of 30 Years of Evidence.

Authors:  Ciro Conversano; Graziella Orrù; Andrea Pozza; Mario Miccoli; Rebecca Ciacchini; Laura Marchi; Angelo Gemignani
Journal:  Int J Environ Res Public Health       Date:  2021-03-11       Impact factor: 3.390

4.  Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management.

Authors:  Ryan Yip; Jennifer Swainson; Atul Khullar; Roger S McIntyre; Kevin Skoblenick
Journal:  Front Psychiatry       Date:  2022-09-29       Impact factor: 5.435

5.  Heart Rate Variability Changes in Patients With Major Depressive Disorder: Related to Confounding Factors, Not to Symptom Severity?

Authors:  Jan Sarlon; Angelica Staniloiu; Andreas Kordon
Journal:  Front Neurosci       Date:  2021-07-05       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.